We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of CP-675,206 in Refractory Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00254579
Recruitment Status : Completed
First Posted : November 16, 2005
Last Update Posted : June 7, 2012
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

Condition or disease Intervention/treatment Phase
Refractory Melanoma Drug: CP-675,206 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 251 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma
Study Start Date : December 2005
Primary Completion Date : December 2009
Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 15 mg/kg CP-675,206 Drug: CP-675,206
15 mg/kg Q12W dosing regimen



Primary Outcome Measures :
  1. To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma [ Time Frame: Tumor response is assessed every 2-3 months until disease progression ]

Secondary Outcome Measures :
  1. Safety [ Time Frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug ]
  2. Pharmaco Kinetic [ Time Frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug ]
  3. Survival [ Time Frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug ]
  4. Health-related QoL [ Time Frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Surgically incurable Stage III or IV melanoma
  • One prior systemic treatment for metastatic melanoma
  • Measurable disease
  • Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1

Exclusion Criteria:

  • Melanoma of ocular origin
  • Received prior vaccine
  • Received prior CTLA4-inhibiting agent
  • History of, or significant risk for, chronic inflammatory or autoimmune disease
  • Potential requirement for systemic corticosteroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254579


  Show 65 Study Locations
Sponsors and Collaborators
AstraZeneca

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00254579     History of Changes
Other Study ID Numbers: A3671008
First Posted: November 16, 2005    Key Record Dates
Last Update Posted: June 7, 2012
Last Verified: June 2012

Keywords provided by AstraZeneca:
refractory melanoma
malignant melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Tremelimumab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs